RaySearch Laboratories AB (publ) RAY-B.ST
Nasdaq Stockholm · Healthcare · Health Information Services
176.70 SEK
+1.0%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for RaySearch Laboratories
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 844 | 1,022 | 1,192 | 1,344 |
| EBITDA | 341 | 406 | 571 | 587 |
| Net income | 24 | 82 | 204 | 228 |
| Balance sheet | ||||
| Equity | 657 | 735 | 877 | 985 |
| Total debt | 555 | 529 | 472 | 395 |
| Cash | 160 | 344 | 463 | 407 |
| Net debt | 395 | 186 | 9 | −12 |
| Ratios and per share | ||||
| EBITDA margin | 40.4% | 39.7% | 47.9% | 43.7% |
| Profit margin | 2.8% | 8.0% | 17.1% | 16.9% |
| Return on equity | 3.6% | 11.1% | 23.2% | 23.1% |
| Earnings/share (SEK) | 0.69 | 2.38 | 5.94 | 6.64 |
| Book value/share (SEK) | 19.17 | 21.45 | 25.57 | 28.74 |
| Shares outstanding (M) | 34 | 34 | 34 | 34 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 26.6 |
| P/B | 6.1 |
| EV / EBITDA | 10.3 |
| Net debt / EBITDA | −0.0 |
| Return on equity | 23.1% |
| Profit margin | 17.0% |
| Beta 1Y | 0.82 |
| Revenue growth 1Y | +12.8% |
| Revenue CAGR 3Y | +16.8% |
| Earnings/share CAGR 3Y | +112.4% |
| ROE avg. 3Y | 19.1% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 4.00 |
| 2025 | 3.00 |
| 2024 | 2.00 |
Not investment advice. Figures may contain errors from the data source.